Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Zimmer Biomet (ZBH)

Zimmer Biomet CFO Suketu Upadhyay to resign; Paul Stellato named interim CFO

Neutral Impact 4 of 5 leadership Written later

Zimmer Biomet said Chief Financial Officer Suketu Upadhyay will resign effective April 28, 2026, to pursue a new professional opportunity. Controller and Chief Accounting Officer Paul Stellato will serve as interim CFO while the company searches for a permanent successor, and the company said Upadhyay's departure did not involve any disagreement on financial or operational matters.

Key points

  • Upadhyay's resignation is effective April 28, 2026; he informed the company on April 22, 2026.
  • Stellato, 51, has been Controller and Chief Accounting Officer since May 2022 and will hold both roles plus interim CFO.
  • Stellato's interim CFO pay includes a $550,000 annual base salary (prorated) and a 2026 target bonus of 70% of base salary.
  • Equity grants with a May 1, 2026 grant date include restricted stock units of about $750,000 and performance-based units of about $100,000.

The filing

CompanyZimmer Biomet (ZBH)
Form8-K, current report
Filed with the SECApr 28, 2026, 6:33 AM ET
Accession number0001193125-26-183430

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.